Jeffrey Bander, MD
Interventional Cardiology · New York, NYNPI 1649438672
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in NY, where the typical reported total is $8,047.
Across 78 payments — averaging $33.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$442
- AstraZeneca$417
- Novartis$287
- Novo Nordisk$270
- Merck$199
- Amgen$185
- plus $800 from 15 others
Across 2 payments — averaging $12,056 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$24K
What the payments were for
- Food & beverage$2,56999%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 3 | $442 |
| AstraZeneca | 12 | $417 |
| Novartis | 16 | $287 |
| Novo Nordisk | 3 | $270 |
| Merck | 8 | $199 |
| Amgen | 7 | $185 |
| Medtronic | 1 | $139 |
| Irhythm Technologies, Inc. | 3 | $112 |
| E.r. Squibb & Sons, L.L.C. | 3 | $74 |
| Alnylam Pharmaceuticals Inc. | 3 | $69 |
| Philips North America LLC | 3 | $56 |
| Abbott | 2 | $52 |
| Johnson & Johnson | 3 | $47 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Bayer | 2 | $37 |
| Heartflow, Inc. | 1 | $30 |
| Bridgebio Pharma, Inc. | 1 | $27 |
| Abiomed | 1 | $27 |
| Bardy Diagnostics, Inc. | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$442
- Reveal LINQ$139
- BRILINTA$132
- LOKELMA$125
- Ozempic$122
How this compares
$2,600 in reported general payments places this provider in the 20th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 403 | $373,264 |
| EntrestoSacubitril/Valsartan | 138 | $141,968 |
| XareltoRivaroxaban | 107 | $128,615 |
| JardianceEmpagliflozin | 108 | $95,165 |
| BrilintaTicagrelor | 76 | $51,658 |
| Repatha SureclickEvolocumab | 58 | $44,415 |
| OzempicSemaglutide | 23 | $28,049 |
| MounjaroTirzepatide | 16 | $18,475 |
| MultaqDronedarone Hcl | 16 | $13,797 |
| FarxigaDapagliflozin Propanediol | 13 | $11,917 |
| Praluent PenAlirocumab | 21 | $11,415 |
| SantylCollagenase Clostridium Hist. | 15 | $7,990 |
| Metoprolol Succinate | 419 | $5,385 |
| Ranolazine ErRanolazine | 91 | $4,879 |
| Meropenem | 17 | $4,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $287 | $141,968138 claims |
| Johnson & JohnsonXarelto | $47 | $128,615107 claims |
| AstraZenecaBrilinta, Farxiga | $417 | $63,57489 claims |
| Novo NordiskOzempic | $270 | $28,04923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Samin SharmaNew York$291K
- Torsten VahlNew York$280K
- George DangasNew York$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.